Vizimpro Europska Unija - hrvatski - EMA (European Medicines Agency)

vizimpro

pfizer europe ma eeig - dacomitinib monohidrat - karcinom, ne-malih stanica pluća - antineoplastična sredstva - vizimpro, kao monoterapija, je propisan za prva linija terapije kod odraslih pacijenata sa lokalno-održao ili метастатического немелкоклеточного raka pluća (НМРЛ) s epidermalnog faktora rasta (egfr) aktiviraju mutacije.

Sapropterin Dipharma Europska Unija - hrvatski - EMA (European Medicines Agency)

sapropterin dipharma

dipharma arzneimittel gmbh - Сапроптерин дигидрохлорид - phenylketonurias - drugi gastrointestinalni trakt i metabolizam, lijekovi, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Ontilyv Europska Unija - hrvatski - EMA (European Medicines Agency)

ontilyv

bial portela & companhia s.a. - opicapone - parkinsonova bolest - antiparkinsonski lijekovi - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Cancidas (previously Caspofungin MSD) Europska Unija - hrvatski - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotika za sustavnu uporabu - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Sorafenib Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Aerius Europska Unija - hrvatski - EMA (European Medicines Agency)

aerius

n.v. organon - dcsloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminici za sistemsku primjenu, - Эриус je propisan za ublažavanje simptoma povezanih s:alergijski rinitis;osip.

Anoro Ellipta (previously Anoro) Europska Unija - hrvatski - EMA (European Medicines Agency)

anoro ellipta (previously anoro)

glaxosmithkline (ireland) limited - bromid umeclidinium, vilanterol trifenatate - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - anoro ellipta navodi kao terapiju održavanja бронходилататор za ublažavanje simptoma kod odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (kopb).

Arava Europska Unija - hrvatski - EMA (European Medicines Agency)

arava

sanofi-aventis deutschland gmbh - leflunomid - arthritis, rheumatoid; arthritis, psoriatic - imunosupresivi - leflunomide indiciran za liječenje odraslih bolesnika s:aktivni reumatoidni artritis kao bolest-mijenjanje противоревматические lijekovi (dmards);aktivni psorijatični artritis. najnovije ili istodobno liječenje гепатотоксичными ili haematotoxic lijekovima (e. metotreksat) može dovesti do povećanog rizika od ozbiljnih nuspojava; stoga treba započeti liječenje leflunomidom pažljivo u vezi s tim aspektima koristi / rizika. osim toga, prebacivanje s лефлуномидом u drugi dmards bez vođenja postupka ispiranja također može povećati rizik od ozbiljnih nuspojava, čak i za dugo nakon komutacije.

Azomyr Europska Unija - hrvatski - EMA (European Medicines Agency)

azomyr

n.v. organon - dcsloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminici za sistemsku primjenu, - azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5. 1)urticaria (see section 5.

Duloxetine Lilly Europska Unija - hrvatski - EMA (European Medicines Agency)

duloxetine lilly

eli lilly nederland b.v. - duloksetin - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - setin lilly prikazan kod odraslih za liječenje osnovne depresivnog disordertreatment dijabetes periferne neuropatske paintreatment generalizirana disorderduloxetine anksioznost lily je navedeno u odraslih.